Nouveau Life Pharmaceuticals, Inc.
NOUV · OTC
12/31/2024 | 6/30/2007 | 6/30/2006 | 6/30/2005 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.90 | 1.14 | -1.02 |
| FCF Yield | 0.00% | -0.26% | -0.73% | -0.88% |
| EV / EBITDA | 0.00 | -41.33 | -54.94 | -38.04 |
| Quality | ||||
| ROIC | 0.00% | 58.91% | -46.41% | -53.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.06 | 0.33 | 0.16 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 73.03% | -32.12% | 20.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.30 | -0.21 | -1.48 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |